Tools
ToolsZeng, Linan, Tian, Jinhui, Song, Fujian, Li, Wenrui, Jiang, Lucan, Gui, Ge, Zhang, Yang, Ge, Long, Shi, Jing, Sun, Gou-Xin, Mu, Dezhi and Zhang, Lingli (2018) Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis. Archives of Disease in Childhood-Fetal and Neonatal Edition, 103 (6). F506-F511. ISSN 1359-2998
Preview |
PDF (Published manuscript)
- Published Version
Available under License Creative Commons Attribution Non-commercial. Download (433kB) | Preview |
Abstract
Objective: To determine the comparative efficacy and safety of corticosteroids in the prevention of bronchopulmonary dysplasia (BPD) in preterm infants. Study design: We systematically searched PubMed, EMBASE and the Cochrane Library. Two reviewers independently selected randomised controlled trials (RCTs) of postnatal corticosteroids in preterm infants. A Bayesian network meta-analysis and subgroup analyses were performed. Results: We included 47 RCTs with 6747 participants. The use of dexamethasone at either high dose or low dose decreased the risk of BPD (OR 0.29, 95% credible interval (CrI) 0.14 to 0.52; OR 0.58, 95% CrI 0.39 to 0.76, respectively). High-dose dexamethasone was more effective than hydrocortisone, beclomethasone and low-dose dexamethasone. Early and long-term dexamethasone at either high dose or low dose decreased the risk of BPD (OR 0.11, 95% CrI 0.02 to 0.4; OR 0.37, 95% CrI 0.16 to 0.67, respectively). There were no statistically significant differences in the risk of cerebral palsy (CP) between different corticosteroids. However, high-dose and long-term dexamethasone ranked lower than placebo and other regimens in terms of CP. Subgroup analyses indicated budesonide was associated with a decreased risk of BPD in extremely preterm and extremely low birthweight infants (OR 0.60, 95% CrI 0.36 to 0.93). Conclusions: Dexamethasone can reduce the risk of BPD in preterm infants. Of the different dexamethasone regimens, aggressive initiation seems beneficial, while a combination of high-dose and long-term use should be avoided because of the possible adverse neurodevelopmental outcome. Dexamethasone and inhaled corticosteroids need to be further evaluated in large-scale RCTs with long-term follow-ups.
| Item Type: | Article |
|---|---|
| Additional Information: | © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) Faculty of Medicine and Health Sciences > Research Centres > Population Health |
| Related URLs: | |
| Depositing User: | Pure Connector |
| Date Deposited: | 02 Mar 2018 14:30 |
| Last Modified: | 25 Sep 2024 13:18 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/66424 |
| DOI: | 10.1136/archdischild-2017-313759 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |